Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.74 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.63 |
| ▸ | LCK | P06239 | 2/20 | 0.49 |
| ▸ | CSF1R | P07333 | 1/20 | 0.44 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4860391 | 0.89 | MAPK14 (0.61) | MAPK14MAPK11LCK | |
| SCHEMBL4857439 | 0.89 | MAPK14 (0.72) | MAPK14MAPK11 | |
| Gw701032X SCHEMBL4857321 | 0.85 | MAPK14 (1.00) | MAPK14MAPK11LCK | |
| SCHEMBL4872468 | 0.83 | MAPK14 (0.82) | MAPK14MAPK11LCKMAP2K1 | |
| SCHEMBL4856527 | 0.82 | MAPK14 (0.74) | MAPK14MAPK11LCK | |
| SCHEMBL5458638 | 0.82 | MAPK14 (0.65) | MAPK14MAPK11MAP2K1 | |
| SCHEMBL4856439 | 0.82 | MAPK14 (1.00) | MAPK14MAPK11LCK | |
| SCHEMBL5467937 | 0.80 | MAPK14 (0.61) | MAPK14MAPK11LCKMAP2K1 | |
| SCHEMBL4862425 | 0.80 | MAPK14 (0.69) | MAPK14MAPK11 | |
| SCHEMBL4854839 | 0.79 | MAPK14 (0.85) | MAPK14MAPK11LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384963-B2 | 2′-Methyl-5-(1,3,4-oxadiazol-2-yl)1, 1′-biphenyl-4-carboxaide derivatives and their use as p38 kinase | GLAXO GROUP LIMITED (GB) | 2008-06-10 | — | — | US | disclosed |
| US-20040266839-A1 | 2'-Methyl-5-(1,3,4-oxadiazol-2-yl)1,1'-biphenyl-4-carboxaide derivatives and their use as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266839-A1 | 2'-Methyl-5-(1,3,4-oxadiazol-2-yl)1,1'-biphenyl-4-carboxaide derivatives and their use as p38 kinase inhibitors | MAPK1, MAPK3, MAPK6 | MAPK14 11/4885MAPK11 17/4885LCK 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.